
NYSEHealthcareMedical - Diagnostics & Research
أحدث البيانات المتاحة
154.18 US$
+2.02 US$ · +1.33%
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
الإغلاق السابق
154.18 US$
+2.02 US$ · +1.33%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
نطاق اليوم
السعر الحالي 154.18 US$
نطاق 52 أسبوعًا
السعر الحالي 154.18 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
احتفاظ
تقييم
65
أقل من القيمة
المشاعر
56
مختلط
المخاطر
34
مخاطر متوسطة
الزخم
52
محايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
نطاق اليوم
السعر الحالي 154.18 US$
نطاق 52 أسبوعًا
السعر الحالي 154.18 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| الإيرادات | 2.86 مليار USD | 2.76 مليار USD | 2.75 مليار USD | 3.31 مليار USD | 3.83 مليار USD |
| تكلفة البضاعة المباعة | 1.34 مليار USD | 1.43 مليار USD | 1.43 مليار USD | 1.55 مليار USD | 1.55 مليار USD |
| الربح الإجمالي | 1.52 مليار USD | 1.32 مليار USD | 1.32 مليار USD | 1.76 مليار USD | 2.28 مليار USD |
| البحث والتطوير | 215.84 مليون USD | 196.84 مليون USD | 216.58 مليون USD | 221.62 مليون USD | 200.34 مليون USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 945.29 مليون USD | 715.3 مليون USD | 706.12 مليون USD | 757.99 مليون USD | 741.61 مليون USD |
| نفقات التشغيل | 1.16 مليار USD | 912.14 مليون USD | 922.7 مليون USD | 979.61 مليون USD | 941.95 مليون USD |
| دخل الفوائد | 31.1 مليون USD | 73.19 مليون USD | 72.13 مليون USD | 3.59 مليون USD | 2.24 مليون USD |
| مصاريف الفوائد | 92.19 مليون USD | 96.28 مليون USD | 98.81 مليون USD | 103.96 مليون USD | 102.13 مليون USD |
| الاستهلاك والإطفاء | 405.34 مليون USD | 427.85 مليون USD | 431.77 مليون USD | 427 مليون USD | 311.44 مليون USD |
| الدخل التشغيلي | 356.64 مليون USD | 410.52 مليون USD | 399.49 مليون USD | 781.12 مليون USD | 1.34 مليار USD |
| صافي الدخل | 241.68 مليون USD | 295.83 مليون USD | −118.38 مليون USD | 569.18 مليون USD | 943.16 مليون USD |
تم تحديث حقائق الشركة 11 أكتوبر 2026.
النتائج المعلنة مع توقعات الإجماع المتاحة.
النتائج المعلنة مع توقعات الإجماع المتاحة.
صناديق متداولة تفصح عن تعرضها لهذا السهم.
State Street SPDR S&P 500 ETF1557.T32.89 مليار0.03%129.35 ترليون JPY0.09%122,850 JP¥+0.12%
Vanguard Morningstar Total Stock Market ETFVTI456.17 مليون0.02%2.3 ترليون USD0.03%381.94 US$+0.63%
Vanguard S&P 500 ETFVOO381.36 مليون0.02%1.8 ترليون USD0.03%715.59 US$+0.61%
Vanguard Morningstar Small-Cap ETFVB330.28 مليون0.18%185.3 مليار USD0.03%289.48 US$+0.64%
iShares Core S&P 500 ETFIVV225.75 مليون0.03%896.44 مليار USD0.03%781.97 US$+0.60%
Vanguard Morningstar Small-Cap Value ETFVBR209.75 مليون0.31%68.2 مليار USD0.05%234.43 US$+0.22%
State Street SPDR S&P 500 ETFSPY207.78 مليون0.03%817.2 مليار USD0.09%778.57 US$+0.60%
Dimensional - US Targeted Value ETFDFAT147.53 مليون0.49%30.12 مليار USD0.33%67.27 US$-0.43%
State Street SPDR S&P 500 ETF1557.T
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard S&P 500 ETFVOO
Vanguard Morningstar Small-Cap ETFVB
iShares Core S&P 500 ETFIVV
Vanguard Morningstar Small-Cap Value ETFVBR
State Street SPDR S&P 500 ETFSPY
Dimensional - US Targeted Value ETFDFATالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.